bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.53 USD
-0.04 (-7.00%)
Updated Sep 6, 2024 04:00 PM ET
Pre-Market: $0.55 +0.02 (3.99%) 9:22 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.53 USD
-0.04 (-7.00%)
Updated Sep 6, 2024 04:00 PM ET
Pre-Market: $0.55 +0.02 (3.99%) 9:22 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of 48.57% and 63.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -61.54% and 1.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 57.14% and 19.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
by Zacks Equity Research
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
by Zacks Equity Research
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
by Zacks Equity Research
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
by Zacks Equity Research
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.46% and 5.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -450% and 4.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
by Zacks Equity Research
Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
by Zacks Equity Research
This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study
by Zacks Equity Research
Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.
Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why
by Zacks Equity Research
Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.
Why bluebird (BLUE) Stock Might be a Great Pick
by Zacks Equity Research
bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
bluebird (BLUE) Stock Down on Raising Additional Capital
by Zacks Equity Research
bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy
by Zacks Equity Research
Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics
by Zacks Equity Research
bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
by Zacks Equity Research
bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%
by Zacks Equity Research
Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.
3 Biotechs With Promising Gene Therapies in the Spotlight
by Ekta Bagri
The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.